Racial-Ethnic Differences in Incident Olanzapine Use After an FDA Advisory for Patients With Schizophrenia
Autor: | Benjamin Lê Cook, G. Caleb Alexander, Stacie B. Dusetzina, Haiden A. Huskamp, Alisa B. Busch |
---|---|
Rok vydání: | 2013 |
Předmět: |
Olanzapine
medicine.medical_specialty medicine.medical_treatment Black People Hyperlipidemias Article White People Benzodiazepines Diabetes mellitus Confidence Intervals Diabetes Mellitus medicine Humans Antipsychotic Psychiatry Medicaid United States Food and Drug Administration business.industry Racial Groups Absolute risk reduction Hispanic or Latino medicine.disease United States Confidence interval Psychiatry and Mental health Schizophrenia Florida Racial/ethnic difference business Antipsychotic Agents Demography medicine.drug |
Zdroj: | Psychiatric Services. 64:83-87 |
ISSN: | 1557-9700 1075-2730 |
Popis: | Prior investigations suggest that olanzapine use declined rapidly after a U.S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown.Changes in olanzapine use over time by race-ethnicity was assessed among 7,901 Florida Medicaid enrollees with schizophrenia.Prior to the advisory, 57% of second-generation antipsychotic fills among Hispanics were for olanzapine, compared with 40% for whites or blacks (adjusted risk difference [ARD]=.17, 95% confidence interval [CI]=.13-.20). Olanzapine use declined among all racial-ethnic groups. Although Hispanics had greater olanzapine use than whites in each period, the differences in absolute risk were only 3% by the latest study period (ARD=.03, CI=.01-.04).After the FDA communication and consensus statement were issued, differences in olanzapine use between white and Hispanic enrollees narrowed considerably. Identifying high-use subgroups for targeted delivery of drug safety information may help eliminate any existing differences in prescribing. |
Databáze: | OpenAIRE |
Externí odkaz: |